Edition:
United States

People: Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

2.39USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,232
52-wk High
$14.22
52-wk Low
$1.98

Aivado, Manuel 

Mr. Manuel C. Aivado is President, Chief Executive Officer, Director of the Company. He has served as our Senior Vice President, Chief Medical Officer since September 2014. From March 2012 until September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 until March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. In addition, Dr. Aivado was an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany. The Company believes that Dr. Aivado is qualified to serve on its Board due to his extensive knowledge of the Company and his significant background in pharmaceutical research and development.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --